Dana-Farber Cancer Institute: Ovarian Neoplasms trials

The registry lists 26 Ovarian Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 6 are open to participants now and 9 have results posted.

Phase 1 6Phase 2 9No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingNCT07832227Phase 2
• REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP InhibitorsRecruitingNCT06710548Not applicable
• Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginRecruitingNCT06677190Phase 2
• Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian CancerRecruitingNCT06543537Not applicable
• Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian CancerRecruitingNCT06321484Phase 1
• Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving ChemotherapyRecruitingNCT04997096Not applicable
• REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related FatigueCompletedNCT04525183Not applicableResults posted
• BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and RenewalCompletedNCT03367247Not applicableResults posted
• Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian CancerCompletedNCT03364673Not applicableResults posted
• Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedNCT03239145Phase 1Results posted
• A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibActive, not recruitingNCT02873962Phase 2Results posted
• Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal CancerCompletedNCT02865811Phase 2Results posted
• Tivozanib As Maintenance Therapy In GYNTerminatedNCT01972516Phase 2Results posted
• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian CancerTerminatedNCT00910000Phase 1/2Results posted
• Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological CancersCompletedNCT00545792Phase 2Results posted
• Video Education With Result Dependent dIsclosureCompletedNCT05225428Not applicable
• SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer CareWithdrawnNCT04368130Not applicable
• Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate CancersCompletedNCT04330716Not applicable
• NeoVax With Nivolumab in Patients With Ovarian CancerActive, not recruitingNCT04024878Phase 1
• Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminatedNCT03277482Phase 1
• Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by CuldocentesisTerminatedNCT02441140Not applicable
• Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot InterventionCompletedNCT02287519Not applicable
• Olaparib for Patients With Recurrent BRCA Deficient Ovarian CancerWithdrawnNCT01661868Phase 2
• Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedNCT01623349Phase 1
• Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual FunctionCompletedNCT00525460
• Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT00230542Phase 2